Stanford team preps first human CRISPR study for sickle cell disease cure; Shkreli fingers his former attorneys
Stanford scientists say they have been able to use CRISPR gene editing tech to correct a faulty gene that triggers sickle cell disease. And now the team wants to take their work into the first human studies for the disease. ”What we’ve finally shown is that we can do it. It’s not just on the chalkboard,” senior author Matthew Porteus tells Reuters.
Mylan and Biocon have submitted the latest biosimilar for an FDA review. This application is for a knockoff of Herceptin for HER-2 positive breast and gastric cancers. Biocon already won an approval in India, marking the first approved biosimilar of Herceptin. Meanwhile, the analysts at Research and Markets recently counted four in late-stage development that appeared to be headed to the market in coming years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.